omniture
logo
Search

/DISREGARD RELEASE: Celltrion/

Celltrion
2025-05-24 00:01 4157

We are advised by Celltrion that journalists and other readers should disregard the news release, Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths, issued 21-May-2025 over PR Newswire.

Source: Celltrion
Related Stocks:
Korea:068270
Media Room more

Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®

2025-12-03 08:43
938

Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA®  (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal

2025-11-26 14:48
1480

U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)

2025-10-30 15:28
1035

FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States

2025-10-17 13:32
1232

Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)

2025-10-10 06:56
1390

Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States

2025-10-02 20:30
1692
Related News

Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab

2025-12-12 10:31
1931

/DISREGARD RELEASE: Ractigen Therapeutics/

2025-12-12 23:10
1913

Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits

2025-12-12 22:00
2712

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

2025-12-12 21:35
2267

Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)

2025-12-12 20:00
1720

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

2025-12-15 08:25
collection